Global Nuclear Medicine Market, By Type, By Diagnostic Nuclear Medicine, By Therapeutic Nuclear Medicine, By Application, By Diagnostic Applications, By Therapeutic Applications, By End User, By Region, Forecast & Opportunities, 2026

Global nuclear medicine market is estimated to grow at an impressive rate during the forecast period owing to increasing incidence and prevalence of diseases like cancer, initiatives to reduce the demand and supply gap of Mo-99 and increasing research and development activities in radiotherapy to treat various diseases. Furthermore, nuclear medicines are extensively being used in molecular imaging, which is a technique involving molecules as biomarkers for specific molecular processes that determines the onset or progress of a disease.

Nuclear medicines are convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Due to this major factor, chemotherapy methods are being replaced by radiopharmaceuticals or nuclear medicines for cancer treatment. They are also used in applications such as lymphoma and bone metastasis. Some of the nuclear medicines used in diagnostic procedures are F-18, Tc-99, Ga-67, and I-123 while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures. These factors are anticipated to drive global nuclear medicine market until 2026.

Apart from above mentioned growth factors, the global nuclear medicine market also faces some restrains. Short half-life of nuclear medicines or radiopharmaceuticals reduces their potential adoption. Other restraining factors include supply shortages, logistical difficulties, and limited number of trained medical personnel.

The global nuclear medicine market is segmented based on therapy, type, application, therapeutics, route of administration, end-user and region. Based on type, the nuclear medicine market is segmented into Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes. Diagnostic Nuclear Medicine can further be split into SPECT Radiopharmaceuticals and PET Radiopharmaceuticals. The SPECT Radiopharmaceuticals segment accounts for the largest market share and is expected to hold its dominance in the coming years owing to low cost and wide usage in different applications.

Major players operating in the global nuclear medicine market include Cardinal Health, Inc., GE Healthcare, Curium SAS, Lantheus Medical Imaging, Inc., Bayer AG, Bracco Imaging S.p.A., Nordion Inc., Novartis AG (Advanced Accelerator Applications SA), Isotopia Molecular Imaging Limited, NorthStar Medical Radioisotopes, LLC and others. Key market players are implementing activities like product developments, business expansion, and collaborative development to maintain significant share in the market for nuclear medicine.

Years considered for this report:

Historical Years: 2016-2019
Base Year: 2020
Estimated Year: 2021
Forecast Period: 2022-2026

Objective of the Study:

To analyze and forecast the market size of global nuclear medicine market.
To classify and forecast global nuclear medicine market based on therapy, type, application, therapeutics, route of administration, end-user, company and regional distribution.
To identify drivers and challenges for global nuclear medicine market.
To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global nuclear medicine market.
To conduct pricing analysis for global nuclear medicine market.
To identify and analyze the profile of leading players operating in global nuclear medicine market.

The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of manufacturers across the globe. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the manufacturers which could not be identified due to the limitations of secondary research. The publisher analyzed the manufacturers, distribution channels and presence of all major players across the globe.

The publisher calculated the market size of global nuclear medicine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Target Audience:

Nuclear medicine manufacturer, suppliers, distributors and other stakeholders
Hospitals & Clinics
Government bodies such as regulating authorities and policy makers
Organizations, forums and alliances related to nuclear medicine
Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global nuclear medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Nuclear Medicine Market, By Type:

Diagnostic Nuclear Medicine
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutic Nuclear Medicine
Alpha Emitters
Beta Emitters
Brachytherapy Isotopes

Global Nuclear Medicine Market, By Application:

Diagnostic Applications
SPECT Applications
PET Applications
Therapeutic Applications
Thyroid Indications
Bone Metastasis
Lymphoma
Endocrine Tumors
Others

Global Nuclear Medicine Market, By End User:

Hospitals & Clinics
Diagnostic Centers
Academic & Research Institutions

Global Nuclear Medicine Market, By Region:

Asia-Pacific
Europe
North America
South America
Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global nuclear medicine market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.

This product will be delivered within 1-3 business days.

1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global Nuclear Medicine Market4. Executive Summary5. Voice of Customer

6. Global Nuclear Medicine Market Outlook

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
6.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
6.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
6.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
6.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
6.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
6.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
6.2.4. By Company (2020)
6.2.5. By Region
6.3. Product Market Map

7. Asia-Pacific Nuclear Medicine Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
7.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
7.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
7.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
7.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
7.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
7.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
7.2.4. By Country
7.3. Asia-Pacific: Country Analysis
7.3.1. China Nuclear Medicine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. India Nuclear Medicine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. Japan Nuclear Medicine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Application
7.3.3.2.3. By End User
7.3.4. South Korea Nuclear Medicine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Application
7.3.4.2.3. By End User
7.3.5. Australia Nuclear Medicine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Application
7.3.5.2.3. By End User

8. Europe Nuclear Medicine Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
8.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
8.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
8.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
8.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
8.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
8.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Nuclear Medicine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. Germany Nuclear Medicine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. United Kingdom Nuclear Medicine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. Italy Nuclear Medicine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Spain Nuclear Medicine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Application
8.3.5.2.3. By End User

9. North America Nuclear Medicine Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
9.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
9.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
9.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
9.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
9.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
9.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
9.2.4. By Country
9.3. North America: Country Analysis
9.3.1. United States Nuclear Medicine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. Mexico Nuclear Medicine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. Canada Nuclear Medicine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Application
9.3.3.2.3. By End User

10. South America Nuclear Medicine Market Outlook

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
10.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
10.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
10.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
10.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
10.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
10.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Nuclear Medicine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Argentina Nuclear Medicine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. Colombia Nuclear Medicine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Application
10.3.3.2.3. By End User

11. Middle East and Africa Nuclear Medicine Market Outlook

11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
11.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
11.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
11.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
11.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
11.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
11.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Nuclear Medicine Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Application
11.3.1.2.3. By End User
11.3.2. Saudi Arabia Nuclear Medicine Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Application
11.3.2.2.3. By End User
11.3.3. UAE Nuclear Medicine Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Application
11.3.3.2.3. By End User

12. Market Dynamics

12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

14.1. Competition Outlook
14.2. Company Profiles (SWOT Analysis of Top 5 Players Profiled)
14.2.1. Cardinal Health, Inc.
14.2.2. GE Healthcare
14.2.3. Curium SAS
14.2.4. Lantheus Medical Imaging, Inc.
14.2.5. Bayer AG
14.2.6. Bracco Imaging S.p.A.
14.2.7. Nordion Inc.
14.2.8. Novartis AG (Advanced Accelerator Applications SA)
14.2.9. Isotopia Molecular Imaging Limited
14.2.10. NorthStar Medical Radioisotopes, LLC

15. Strategic Recommendations

16. About Us & Disclaimer

(Note: The companies list can be customized based on the client requirements)